Allianz Asset Management GmbH grew its holdings in HUTCHISON CHINA/S (NASDAQ:HCM) by 47.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 447,494 shares of the company’s stock after buying an additional 143,765 shares during the period. Allianz Asset Management GmbH owned approximately 0.34% of HUTCHISON CHINA/S worth $14,405,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also modified their holdings of the business. Royal Bank of Canada purchased a new position in shares of HUTCHISON CHINA/S during the 1st quarter worth about $199,000. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of HUTCHISON CHINA/S by 12.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 121,430 shares of the company’s stock worth $3,660,000 after purchasing an additional 13,345 shares during the period. Alps Advisors Inc. purchased a new position in shares of HUTCHISON CHINA/S during the 2nd quarter worth about $5,785,000. GSA Capital Partners LLP boosted its stake in shares of HUTCHISON CHINA/S by 10.5% during the 2nd quarter. GSA Capital Partners LLP now owns 222,345 shares of the company’s stock worth $6,701,000 after purchasing an additional 21,077 shares during the period. Finally, Bellevue Group AG boosted its stake in shares of HUTCHISON CHINA/S by 10.0% during the 2nd quarter. Bellevue Group AG now owns 332,536 shares of the company’s stock worth $10,023,000 after purchasing an additional 30,116 shares during the period. 11.79% of the stock is owned by institutional investors and hedge funds.
HCM has been the subject of a number of recent analyst reports. BidaskClub cut shares of HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a research note on Thursday, August 23rd. Zacks Investment Research raised shares of HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a research note on Thursday, November 15th.
HUTCHISON CHINA/S stock opened at $31.62 on Monday. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of -143.73 and a beta of 0.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.67 and a quick ratio of 4.55. HUTCHISON CHINA/S has a 1 year low of $25.76 and a 1 year high of $42.25.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/12/10/allianz-asset-management-gmbh-acquires-143765-shares-of-hutchison-china-s-hcm.html.
HUTCHISON CHINA/S Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Read More: How is the S&P 500 index different from the DJIA?
Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.